Posters

Myoring implantation after protrusion of intrastromal segments in patients with keratoconus

Poster Details

First Author: E.Usubov RUSSIA

Co Author(s):    M. Bikbov   G. Kazakbayeva   K. Oganisyan              

Abstract Details

Purpose:

To study the efficiency of MyoRing intrastromal implantation to correct residual ametropia in patients with keratoconus after segment extrusion

Setting:

Ufa Eye Research Institute. 95 cases with keratoconus stage I-III by Amsler were studied

Methods:

The patients previously underwent the correction of ametropia with Keraring ICRS implantation. 6 patients (6.3%) had a protrusion of the segment in terms of 3-8 months, segment explantation was required. MyoRing implantation in order to correct ametropia no earlier than six months after explantation and complete healing of the cornea was perfomed using a Pocket Maker microkeratome (Dioptex, Austria). Standard and additional ophthalmological examinations, including corneal topography (ORB-scan), pachymetry and optical coherence tomography (OCT, Carl Zeiss), confocal microscopy (HRT II, Heldlberg Enjeneering) were done. The follow-up period after ring implantation was 12 months

Results:

Uncorrected visual acuity (UCVA) increased from an average of 0.06±0.02 to 0.3±0.15 after 1 month MyoRing implantation, corrected visual acuity (CVA) - from 0.1±0.02 to 0.6±0.23. Refractive power of the cornea decreased: the average with 55.65±5.35D up to 43.1±4.25D, in a steep meridian – from 59.20±3.25D to 47.1±3.16D, in a flat meridian - from 49.15±3.25D to 44.1±2.55D. Corneal thickness at the center had a tendency to increase on average by 20-30 microns. After 6 months UCVA increased from 0.3±0.15 to 0.5±0.2, CVA - from 0.6±0.23 to 0.8±0.18 and remained stable. No case of Myoring protrusion was observed.

Conclusions:

Myoring implantation in patients with keratoconus is an effective technique in ametropia correction in complicated cases after segment explantation and provides the improvement of the clinical and functional parameters

Financial Disclosure:

NONE